US69366J2006 - Common Stock - After market: 46.25 0 (0%)
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o National Institute for Health and Care Excellence (NICE) publicou um Documento de...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que el National Institute for Health and Care Excellence (NICE) ha publicado un documento de...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P. Morgan...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P. Morgan...
While loyalty may be a positive trait in most circumstances, when it comes to Nasdaq stocks to sell, you got to look out for number one.
/PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária) aprovou o Waylivra™...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil, ANVISA (Agência Nacional de...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted authorization by the Medicines and...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2022...
/PRNewswire/ -- A PTC Therapeutics, Inc. (NASDAQ: PTCT) anuncia que uma associação de pacientes brasileira é uma das quatro ganhadoras do programa global...